HSPB6 and neoplasm: Moreover, analysis of data from the Clinical Proteomic Tumor Analysis Consortium (CPTAC) revealed that high HSPB6 expression correlates with longer overall survival in patients with PDAC, indicating its potential as a prognostic marker [27].